Antibe Therapeutics Inc
TSX:ATE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Yiren Digital Ltd
NYSE:YRD
|
CN |
|
M
|
MultiChoice Group Ltd
JSE:MCG
|
ZA |
Antibe Therapeutics Inc
Research & Development
Antibe Therapeutics Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Antibe Therapeutics Inc
TSX:ATE
|
Research & Development
-CA$10.1m
|
CAGR 3-Years
7%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
-38%
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Research & Development
-$629m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-7%
|
|
|
Sundial Growers Inc
NASDAQ:SNDL
|
Research & Development
-CA$489k
|
CAGR 3-Years
41%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
Cronos Group Inc
TSX:CRON
|
Research & Development
-$4.4m
|
CAGR 3-Years
30%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Research & Development
-$105.2m
|
CAGR 3-Years
-41%
|
CAGR 5-Years
-61%
|
CAGR 10-Years
-152%
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Research & Development
-CA$27.1m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
-26%
|
|
Antibe Therapeutics Inc
Glance View
Antibe Therapeutics, Inc. is a biotechnology company, which engages in the development of medicines for pain and inflammation. The company is headquartered in Toronto, Ontario and currently employs 37 full-time employees. The company went IPO on 2013-06-18. The firm is focused on pain, inflammation, and regenerative medicine. The Company’s products pipeline includes Otenaproxesul, ATB-352, and ATB-340. Otenaproxesul is a novel anti-inflammatory drug that releases hydrogen sulfide and combines hydrogen sulfide with naproxen, non-steroidal, anti-inflammatory drug. ATB-352 is a hydrogen sulfide-releasing derivative of ketoprofen. ATB-340 is a gastrointestinal-safe version of low-dose aspirin for cardiovascular and cancer protection. The Company, through its wholly owned subsidiary, Citagenix Inc. (Citagenix) is a seller of tissue regenerative products servicing the orthopaedic and dental marketplaces. Citagenix’s portfolio consists of branded biologics and medical devices that promote bone regeneration.
See Also
What is Antibe Therapeutics Inc's Research & Development?
Research & Development
-10.1m
CAD
Based on the financial report for Sep 30, 2023, Antibe Therapeutics Inc's Research & Development amounts to -10.1m CAD.
What is Antibe Therapeutics Inc's Research & Development growth rate?
Research & Development CAGR 10Y
-38%
Over the last year, the Research & Development growth was 27%. The average annual Research & Development growth rates for Antibe Therapeutics Inc have been 7% over the past three years , -24% over the past five years , and -38% over the past ten years .
